NasdaqGS:APTX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Aptinyx's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: APTX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-13.0%

APTX

0.2%

US Biotechs

2.8%

US Market


1 Year Return

6.2%

APTX

25.7%

US Biotechs

9.3%

US Market

Return vs Industry: APTX underperformed the US Biotechs industry which returned 27.3% over the past year.

Return vs Market: APTX exceeded the US Market which returned 9.9% over the past year.


Shareholder returns

APTXIndustryMarket
7 Day-13.0%0.2%2.8%
30 Day32.7%9.1%8.9%
90 Day13.5%11.9%-0.5%
1 Year6.2%6.2%26.9%25.7%11.8%9.3%
3 Yearn/a34.8%30.3%31.4%22.7%
5 Yearn/a-2.5%-8.3%58.7%40.9%

Price Volatility Vs. Market

How volatile is Aptinyx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Aptinyx undervalued compared to its fair value and its price relative to the market?

1.34x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate APTX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate APTX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: APTX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: APTX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate APTX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: APTX is good value based on its PB Ratio (1.4x) compared to the US Biotechs industry average (3.7x).


Next Steps

Future Growth

How is Aptinyx forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

-5.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: APTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: APTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: APTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: APTX's revenue (45.3% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: APTX's revenue (45.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if APTX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Aptinyx performed over the past 5 years?

-29.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: APTX is currently unprofitable.

Growing Profit Margin: APTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: APTX is unprofitable, and losses have increased over the past 5 years at a rate of -29.6% per year.

Accelerating Growth: Unable to compare APTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: APTX has a negative Return on Equity (-45.23%), as it is currently unprofitable.


Next Steps

Financial Health

How is Aptinyx's financial position?


Financial Position Analysis

Short Term Liabilities: APTX's short term assets ($126.1M) exceed its short term liabilities ($4.6M).

Long Term Liabilities: APTX's short term assets ($126.1M) exceed its long term liabilities ($234.0K).


Debt to Equity History and Analysis

Debt Level: APTX is debt free.

Reducing Debt: APTX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: APTX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: APTX has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 23.4% each year.


Next Steps

Dividend

What is Aptinyx's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate APTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate APTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if APTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APTX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of APTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Norbert Riedel (61yo)

5yrs

Tenure

US$5,635,424

Compensation

Dr. Norbert G. Riedel, Ph.D., serves as Board Member at TRACT Therapeutics, Inc. He serves as Chairman of Eton Pharmaceuticals, Inc., since September 2018 and serves as Industry Advisor at Agent Capital, L ...


CEO Compensation Analysis

Compensation vs Market: Norbert's total compensation ($USD5.64M) is above average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: Norbert's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Norbert Riedel
President5yrsUS$5.64m2.2% $3.6m
Ashish Khanna
CFO & Chief Business Officer2.33yrsUS$2.12m0.62% $1.0m
Andrew Kidd
Chief Operating Officer1.25yrsUS$2.12m0.020% $33.0k
Juan Estupinan
Vice President of Finance & Accounting and Controller1.25yrsno datano data
Patricia Adams
Senior Vice President of Human Resources & Administration1.25yrsno datano data
Nicholas Smith
Director of Corporate Developmentno datano datano data
Joseph Moskal
Senior Scientific Advisor0.83yrUS$497.86kno data
Kathryn King
Senior Vice President - Clinical Development1.42yrsno datano data
Rolando Gutierrez-Esteinou
Senior Vice President of Medical & Pharmacovigilance0.42yrno datano data

1.3yrs

Average Tenure

52yo

Average Age

Experienced Management: APTX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Norbert Riedel
President5yrsUS$5.64m2.2% $3.6m
Elisha Gould
Independent Director4.92yrsUS$131.05kno data
Patrick Enright
Independent Chairman of the Board0.083yrUS$137.55k0.21% $343.0k
Adam Koppel
Independent Director2.5yrsUS$136.05kno data
Robert Hombach
Independent Director2.08yrsUS$141.05k0.33% $538.3k
Rachel Sherman
Independent Director0.75yrUS$182.91k0.0048% $7.8k
Henry Gosebruch
Independent Director1.08yrsUS$215.38k0.27% $451.3k

2.1yrs

Average Tenure

58yo

Average Age

Experienced Board: APTX's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 36%.


Top Shareholders

Company Information

Aptinyx Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aptinyx Inc.
  • Ticker: APTX
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$164.817m
  • Shares outstanding: 45.66m
  • Website: https://www.aptinyx.com

Number of Employees


Location

  • Aptinyx Inc.
  • 909 Davis Street
  • Suite 600
  • Evanston
  • Illinois
  • 60201
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
APTXNasdaqGS (Nasdaq Global Select)COMUSUSDNo data
APTXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2018

Biography

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson’s disease cognitive impairment. The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/02 05:16
End of Day Share Price2020/06/01 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.